Relationship between T cells, dendritic cells could prevent organ rejection

Study into the link between T cells and dendritic cells could lead to reduced rates of organ rejection in transplant patients.

A worldwide team lead by researchers at the University of Pittsburgh School of Medicine studied just how T cells work in the rejection of transplanted organs in the receiver’s body. When immunosuppressive drugs are not taken, the T cells in the body attack the new organ when activated. Researchers set out to study just how these cells become activated and found a way to stop the activation, which has the potential for researchers to develop a new method for preventing the rejection of donor organs.

When studying T cell activation in mice, the researchers concluded that dendritic cells become activated when come into contact with T cells. In mice with kidney and spleen transplants, the donor dendritic cells were being replaced by the organ recipient’s dendritic cells. This replacement of dendritic cells promoted the activation of T cells within the transplant and increased the rate of organ rejection.

"We demonstrated that dendritic cells not only exert a key role as antigen-presenting cells in graft-draining lymphoid organs, but also play a critical function within the transplanted organs," wrote co-author Adrian E. Morelli, MD, PhD, et al. "Our study indicates that eliminating transplant-infiltrating dendritic cells reduces proliferation and survival of T cells within the graft with the consequent prolongation of transplant survival."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.